273 related articles for article (PubMed ID: 26501109)
1. Investigating Reports of Complex Regional Pain Syndrome: An Analysis of HPV-16/18-Adjuvanted Vaccine Post-Licensure Data.
Huygen F; Verschueren K; McCabe C; Stegmann JU; Zima J; Mahaux O; Van Holle L; Angelo MG
EBioMedicine; 2015 Sep; 2(9):1114-21. PubMed ID: 26501109
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
[TBL] [Abstract][Full Text] [Related]
3. Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase
Chandler RE; Juhlin K; Fransson J; Caster O; Edwards IR; Norén GN
Drug Saf; 2017 Jan; 40(1):81-90. PubMed ID: 27638661
[TBL] [Abstract][Full Text] [Related]
4. Safety and perception: What are the greatest enemies of HPV vaccination programmes?
Bonanni P; Zanella B; Santomauro F; Lorini C; Bechini A; Boccalini S
Vaccine; 2018 Aug; 36(36):5424-5429. PubMed ID: 28610824
[TBL] [Abstract][Full Text] [Related]
5. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience.
Angelo MG; Zima J; Tavares Da Silva F; Baril L; Arellano F
Pharmacoepidemiol Drug Saf; 2014 May; 23(5):456-65. PubMed ID: 24644078
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of Upper Limb Complex Regional Pain Syndrome in a Retrospective Cohort of Persons Aged 9-30 Years, 2002-2017.
Naleway AL; Henninger ML; Irving SA; Bianca Salas S; Kauffman TL; Crane B; Mittendorf KF; Harsh S; Elder C; Gee J
Perm J; 2023 Jun; 27(2):75-86. PubMed ID: 37154719
[TBL] [Abstract][Full Text] [Related]
8. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
Schwarz TF
Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
[TBL] [Abstract][Full Text] [Related]
9. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.
Romanowski B; Schwarz TF; Ferguson L; Peters K; Dionne M; Behre U; Schulze K; Hillemanns P; Suryakiran P; Thomas F; Struyf F
Hum Vaccin Immunother; 2016; 12(1):20-9. PubMed ID: 26176261
[TBL] [Abstract][Full Text] [Related]
10. Strategies for continuous evaluation of the benefit-risk profile of HPV-16/18-AS04-adjuvanted vaccine.
Angelo MG; Taylor S; Struyf F; Tavares Da Silva F; Arellano F; David MP; Dubin G; Rosillon D; Baril L
Expert Rev Vaccines; 2014 Nov; 13(11):1297-306. PubMed ID: 25219284
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
[TBL] [Abstract][Full Text] [Related]
12. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls.
Pedersen C; Breindahl M; Aggarwal N; Berglund J; Oroszlán G; Silfverdal SA; Szüts P; O'Mahony M; David MP; Dobbelaere K; Dubin G; Descamps D
J Adolesc Health; 2012 Jan; 50(1):38-46. PubMed ID: 22188832
[TBL] [Abstract][Full Text] [Related]
14. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years.
Schwarz TF; Huang LM; Medina DM; Valencia A; Lin TY; Behre U; Catteau G; Thomas F; Descamps D
J Adolesc Health; 2012 Feb; 50(2):187-94. PubMed ID: 22265115
[TBL] [Abstract][Full Text] [Related]
15. Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation.
Larson HJ; Wilson R; Hanley S; Parys A; Paterson P
Hum Vaccin Immunother; 2014; 10(9):2543-50. PubMed ID: 25483472
[TBL] [Abstract][Full Text] [Related]
16. Six-year multi-centre, observational, post-marketing surveillance of the safety of the HPV-16/18 AS04-adjuvanted vaccine in women aged 10-25 years in Korea.
Kim CJ; Song R; Chen J; Tavares Da Silva F; Gopala KB; Kim JH; Bi D; Park JS
Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):837-842. PubMed ID: 28266092
[TBL] [Abstract][Full Text] [Related]
17. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women.
Petäjä T; Pedersen C; Poder A; Strauss G; Catteau G; Thomas F; Lehtinen M; Descamps D
Int J Cancer; 2011 Nov; 129(9):2147-57. PubMed ID: 21190190
[TBL] [Abstract][Full Text] [Related]
18. Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.
Szarewski A
Expert Rev Vaccines; 2012 Jun; 11(6):645-57. PubMed ID: 22873123
[TBL] [Abstract][Full Text] [Related]
19. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.
Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; de Borba PC; Sanchez N; Zahaf T; Catteau G; Geeraerts B; Descamps D
Hum Vaccin Immunother; 2014; 10(8):2147-62. PubMed ID: 25424918
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases.
Skinner SR; Apter D; De Carvalho N; Harper DM; Konno R; Paavonen J; Romanowski B; Roteli-Martins C; Burlet N; Mihalyi A; Struyf F
Expert Rev Vaccines; 2016; 15(3):367-87. PubMed ID: 26902666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
